Innovating Works

ALMAC DISCOVERY

Desconocido
MM_BH3_CutTag: Parallel epigenomic and apoptotic profiling to identify targetable sensitivities in Multiple Myeloma ALMAC DISCOVERY LTD participó en un HORIZON EUROPE: HORIZON-MSCA-2021-PF-01 Multiple Myeloma (MM) is an incurable cancer caused by uncontrolled growth of the plasma cells. A major challenge is drug resistance, which...
2022-08-02 - 2024-08-31 | Financiado
TACT: Targeted Anti Cancer Therapies ALMAC DISCOVERY LTD participó en un H2020: H2020-MSCA-ITN-2019 Antibody-Drug Conjugates (ADCs) are fast growing classes of oncology therapeutics. They consist in a highly potent cytotoxic drug connected...
2020-02-05 - 2024-03-31 | Financiado
APPFlow: Active Pharmaceutical Production in Flow ALMAC DISCOVERY LTD participó en un H2020: H2020-MSCA-ITN-2018 APPFlow will develop Early Stage Researchers (ESRs) in innovative research through a focussed training plan centred on flow chemistry, essen...
2018-08-22 - 2023-06-30 | Financiado
ONCORNET: ONCOgenic Receptor Network of Excellence and Training ALMAC DISCOVERY LTD participó en un H2020: H2020-MSCA-ITN-2014 Cancer is a leading health concern. There is a need to fully understand the fundamental processes underlying development of cancer. There is...
2014-12-16 - 2019-05-31 | Financiado
FLUOR21: FLUOR21 Synthesis structure and function of fluorinated systems ALMAC DISCOVERY LTD participó en un FP7: "Organofluorine chemistry has played a significant role in the majority of the spectacular scientific and technological developments of the...
Financiado
* Datos extraídos de la documentos o webs disponibles en diferentes organismos públicos.